Study of Ribociclib for HR+ HER2-negative breast cancer in Russia
Treatments studied
Part of Cancer, Skin clinical trials.
This study looks at how well ribociclib works when given with hormone therapy after surgery for certain types of breast cancer. It aims to understand real-world benefits and safety for patients in Russia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with stage II or III breast cancer that is hormone receptor positive and HER2 negative.
- You have had radical treatment (like surgery) for your breast cancer.
- You have started hormone therapy with an aromatase inhibitor with or without a GnRH agonist within the last 12 months.
- You have an ECOG performance status of 0 or 1, meaning you are fully active or only limited in physical activity.
- You have not used abemaciclib, palbociclib, or other CDK4/6 inhibitors before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of ribociclib and anastrozole as a first treatment for advanced hormone receptor-positive, HER2-negative breast cancer that has not been treated before. It may help if you have not received any prior therapy for metastatic disease.
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
This trial tests ribociclib, a targeted therapy, for women with hormone receptor-positive, HER2-negative breast cancer who still have cancer cells in the breast or lymph nodes after initial chemotherapy. It aims to reduce the chance of cancer coming back.
This study tracks how well patients take ribociclib (a cancer-fighting drug) combined with hormone therapy for early-stage breast cancer, and monitors for any side effects. The goal is to understand real-world use and help patients stay on treatment safely.
This trial tests whether some people with hormone receptor-positive, HER2-negative early breast cancer can safely receive less chemotherapy when also taking the targeted drug ribociclib after surgery. You may qualify if you have a specific stage of breast cancer and are planning to take hormone therapy for at least 5 years.
This trial tests adding ribociclib (a targeted pill) to standard hormone therapy for people with early but high-risk HR-positive, HER2-negative breast cancer, after surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.